Sucroferric Oxyhydroxide — Membership Pricing

Other medications in Nephrology

• Lanthanum Carbonate
• Patiromer
• Sevelamer
• Sodium Zirconium Cyclosilicate

About Sucroferric Oxyhydroxide

For individuals managing chronic kidney disease, controlling phosphate levels is crucial. Sucroferric oxyhydroxide is a medication designed to help achieve this, improving quality of life. At TheDrugClub, we understand the financial burden of essential prescriptions. Our membership program is dedicated to helping you access sucroferric oxyhydroxide and other vital medications at more affordable prices.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Sucroferric Oxyhydroxide is approved for (FDA label)

Velphoro is indicated for the control of serum phosphorus levels in adults and pediatric patients 9 years of age and older with chronic kidney disease (CKD) on dialysis. Velphoro is a phosphate binder indicated for the control of serum phosphorus levels in adult and pediatric patients 9 years of age and older with chronic kidney disease on dialysis. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: April 1, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Sucroferric Oxyhydroxide (FDA label)

Velphoro is supplied in a strength of 500 mg as a brown, circular, bi-planar chewable tablet embossed with "PA 500" on one side. Each chewable tablet contains 500 mg iron (equivalent to 2,500 mg sucroferric oxyhydroxide). Velphoro chewable tablet 500 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 237da26c-f38c-4faa-93ad-735e71c9d0c1. SPL document ID: 4e6c954e-7710-efc7-e063-6394a90a6dc2. Label effective date: April 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Sucroferric Oxyhydroxide (FDA label)

The most common adverse drug reactions to Velphoro chewable tablets in clinical trials were discolored feces (12%) and diarrhea (6%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care Renal Therapies Group, LLC at 1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Adult Patients Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data derived from Velphoro clinical trials reflect exposure to Velphoro in 2 active-controlled clinical studies involving a total of 778 adult patients on hemodialysis and 57 adult patients on peritoneal dialysis exposed for up to 55 weeks. Dosage regimens ranged from 250 mg to 3,000 mg per day. In a parallel design, dose-finding study of Velphoro with a treatment duration of 6 weeks in hemodialysis patients, adverse reactions for Velphoro (N=128) were similar to those reported for the active-control group (sevelamer hydrochloride) (N=26), with the exception of discolored feces (12%) which did not occur in the active-control group. Diarrhea was reported in 6% of patients treated with Velphoro. In a 55-week, open-label, active-controlled, parallel design, safety and efficacy study involving 968 hemodialysis patients and 86 peritoneal dialysis patients treated with either Velphoro (N=707 including 57 peritoneal dialysis patients) or the active-control (sevelamer carbonate) (N=348 including 29 peritoneal dialysis patients), adverse reactions occurring in more than 5% in the Velphoro group were diarrhea (24%), discolored feces (16%), and nausea (10%). The majority of diarrhea events in the Velphoro group were mild and transient, occurring soon after initiation of treatment, and resolving with continued treatment. Adverse reactions occurred at similar rates in hemodialysis and peritoneal dialysis patients. The most common adverse reactions (>1%) leading to withdrawal were diarrhea (4%), product taste abnormal (2%), and nausea (2%).

Source: FDA prescribing information (DailyMed). Set ID: 237da26c-f38c-4faa-93ad-735e71c9d0c1. SPL document ID: 4e6c954e-7710-efc7-e063-6394a90a6dc2. Label effective date: April 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Sucroferric Oxyhydroxide (FDA label)

None. None ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 237da26c-f38c-4faa-93ad-735e71c9d0c1. SPL document ID: 4e6c954e-7710-efc7-e063-6394a90a6dc2. Label effective date: April 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Sucroferric Oxyhydroxide (FDA label)

Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, history of recent major gastrointestinal surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients. ( 5.1 ) 5.1 Monitoring in Patients with Gastrointestinal Disorders or Iron Accumulation Disorders Each chewable tablet contains 500 mg iron (equivalent to 2,500 mg sucroferric oxyhydroxide) [see Clinical Pharmacology (12.3) ] . Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.

Source: FDA prescribing information (DailyMed). Set ID: 237da26c-f38c-4faa-93ad-735e71c9d0c1. SPL document ID: 4e6c954e-7710-efc7-e063-6394a90a6dc2. Label effective date: April 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Sucroferric Oxyhydroxide (FDA label)

Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Oral medications not listed in Table 1 There are no empirical data on avoiding drug interactions between Velphoro and most concomitant oral drugs. For oral medications where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, consider separating the administration of the two drugs. The necessary separation depends upon the absorption characteristics of the medication concomitantly administered, such as the time to reach peak systemic levels and whether the drug is an immediate-release or an extended-release product.

Source: FDA prescribing information (DailyMed). Set ID: 237da26c-f38c-4faa-93ad-735e71c9d0c1. SPL document ID: 4e6c954e-7710-efc7-e063-6394a90a6dc2. Label effective date: April 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.